Related references
Note: Only part of the references are listed.Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation
A. S. Slingerland et al.
DIABETIC MEDICINE (2008)
Neonatal diabetes mellitus
Lydia Aguilar-Bryan et al.
ENDOCRINE REVIEWS (2008)
The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy
Joseph C. Koster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Insulin mutation screening in 1,044 patients with diabetes:: Mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood
Emma L. Edghill et al.
DIABETES (2008)
Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11
Woj Ciech Mlynarski et al.
NATURE CLINICAL PRACTICE NEUROLOGY (2007)
Molecular basis of neonatal diabetes in Japanese patients
Shigeru Suzuki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A novel mutation causing DEND syndrome -: A treatable channelopathy of pancreas and brain
K. Shimomura et al.
NEUROLOGY (2007)
Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2
Nadia Bahi-Buisson et al.
JOURNAL OF CHILD NEUROLOGY (2007)
Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects
Sian Ellard et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2007)
An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive fonn of developmental delay, epilepsy, and neonatal diabetes
Ricard Masia et al.
DIABETES (2007)
Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene
A. S. Slingerland et al.
DIABETOLOGIA (2006)
Activating mutations in the ABCC8 gene in neonatal diabetes mellitus
Andrey P. Babenko et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Ewan R. Pearson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features
Anna L. Gloyn et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2006)
Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype
SE Flanagan et al.
DIABETOLOGIA (2006)
Activating mutations in Kir6.2 and neonatal diabetes - New clinical syndromes, new scientific insights, and new therapy
AT Hattersley et al.
DIABETES (2005)
Neonatal diabetes mellitus: from understudy to center stage
MA Sperling
CURRENT OPINION IN PEDIATRICS (2005)
The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes:: evidence for heterogeneity of beta cell function among carriers of the R201H mutation
T Klupa et al.
DIABETOLOGIA (2005)
High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation
E Codner et al.
DIABETES CARE (2005)
Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes
AL Gloyn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features
P Proks et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2
A Zung et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2 -: Patient characteristics and initial response to sulfonylurea therapy
JV Sagen et al.
DIABETES (2004)
Share Paper
